CompletedPhase 3NCT00653068
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Alyssa T Reddy, M.DChildren's Oncology Group
- Intervention
- 3-Dimensional Conformal Radiation Therapy(radiation)
- Enrollment
- 70 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2009 – 2024
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Valley Children's Hospital, Madera, California, United States
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Rady Children's Hospital - San Diego, San Diego, California, United States
- UCSF Medical Center-Parnassus, San Francisco, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00653068 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University